RVNC logo

Revance Therapeutics (RVNC) Company Overview

Profile

Full Name:

Revance Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 6, 2014

Indexes:

Not included

Description:

Revance Therapeutics (RVNC) is a biotechnology company focused on developing innovative treatments for various medical conditions. They specialize in neuromodulators and other therapies, aiming to improve patient outcomes in areas like aesthetics and therapeutic applications. Their products include DaxibotulinumtoxinA for cosmetic and therapeutic uses.

Key Details

Price

$3.65

Annual Revenue

$234.04 M(+76.55% YoY)

Annual EPS

-$3.83(+21.84% YoY)

Annual ROE

213.71%

Beta

1.42

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 17, 25 Needham
Hold
Dec 23, 24 Barclays
Equal-Weight
Dec 10, 24 Mizuho
Neutral
Nov 8, 24 Needham
Hold
Nov 8, 24 HC Wainwright & Co.
Neutral
Oct 28, 24 Needham
Hold
Sep 13, 24 Barclays
Equal-Weight
Aug 13, 24 Needham
Hold
Aug 12, 24 William Blair
Market Perform
Aug 12, 24 Guggenheim
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
RVNC
accessnewswire.comFebruary 7, 2025

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=127798&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
RVNC
prnewswire.comFebruary 7, 2025

NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
RVNC
globenewswire.comFebruary 6, 2025

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc.
RVNC
accessnewswire.comFebruary 6, 2025

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").

The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
RVNC
prnewswire.comFebruary 6, 2025

NEW YORK , Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
RVNC
accessnewswire.comFebruary 6, 2025

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=127628&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Revance Therapeutics Inc
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Revance Therapeutics Inc
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Revance Therapeutics Inc
RVNC
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
RVNC
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
RVNC
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=127227&wire=1 or contact Joseph E. Levi, Esq.

RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
RVNC
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").

FAQ

  • What is the ticker symbol for Revance Therapeutics?
  • Does Revance Therapeutics pay dividends?
  • What sector is Revance Therapeutics in?
  • What industry is Revance Therapeutics in?
  • What country is Revance Therapeutics based in?
  • When did Revance Therapeutics go public?
  • Is Revance Therapeutics in the S&P 500?
  • Is Revance Therapeutics in the NASDAQ 100?
  • Is Revance Therapeutics in the Dow Jones?
  • When was Revance Therapeutics's last earnings report?
  • When does Revance Therapeutics report earnings?
  • Should I buy Revance Therapeutics stock now?

What is the ticker symbol for Revance Therapeutics?

The ticker symbol for Revance Therapeutics is NASDAQ:RVNC

Does Revance Therapeutics pay dividends?

No, Revance Therapeutics does not pay dividends

What sector is Revance Therapeutics in?

Revance Therapeutics is in the Healthcare sector

What industry is Revance Therapeutics in?

Revance Therapeutics is in the Biotechnology industry

What country is Revance Therapeutics based in?

Revance Therapeutics is headquartered in United States

When did Revance Therapeutics go public?

Revance Therapeutics's initial public offering (IPO) was on February 6, 2014

Is Revance Therapeutics in the S&P 500?

No, Revance Therapeutics is not included in the S&P 500 index

Is Revance Therapeutics in the NASDAQ 100?

No, Revance Therapeutics is not included in the NASDAQ 100 index

Is Revance Therapeutics in the Dow Jones?

No, Revance Therapeutics is not included in the Dow Jones index

When was Revance Therapeutics's last earnings report?

Revance Therapeutics's most recent earnings report was on Nov 7, 2024

When does Revance Therapeutics report earnings?

The next expected earnings date for Revance Therapeutics is Feb 28, 2025

Should I buy Revance Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions